Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Jeea Choi"'
Autor:
Pedro Marques Ramos, Jeea Choi, Catarina D. Campbell, Ying A. Wang, Celine Pallaud, Michael Dickinson, Amit Verma, Moshe Mittelman, Uwe Platzbecker, Honar Cherif, Pierre Fenaux
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 876-881 (2023)
Abstract Eltrombopag has been previously shown to be effective in reversing azacitidine‐mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus azacitidine i
Externí odkaz:
https://doaj.org/article/1a4eb4e4b59b4fa7b1cc250080b778b7
Autor:
Jeffrey R. Jones, Linghai Kong, Michael G. Hanna, IV, Brianna Hoffman, Robert Krencik, Robert Bradley, Tracy Hagemann, Jeea Choi, Matthew Doers, Marina Dubovis, Mohammad Amin Sherafat, Anita Bhattacharyya, Christina Kendziorski, Anjon Audhya, Albee Messing, Su-Chun Zhang
Publikováno v:
Cell Reports, Vol 25, Iss 4, Pp 947-958.e4 (2018)
Summary: How mutations in glial fibrillary acidic protein (GFAP) cause Alexander disease (AxD) remains elusive. We generated iPSCs from two AxD patients and corrected the GFAP mutations to examine the effects of mutant GFAP on human astrocytes. AxD a
Externí odkaz:
https://doaj.org/article/8661b3e265394aa380281091f516e8d2
Autor:
Eric Bouffet, Birgit Geoerger, Christopher Moertel, James A. Whitlock, Isabelle Aerts, Darren Hargrave, Lisa Osterloh, Eugene Tan, Jeea Choi, Mark Russo, Elizabeth Fox
Publikováno v:
Journal of Clinical Oncology. 41:664-674
PURPOSE BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). Here, we describe a phase I/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as
Autor:
James A. Whitlock, Birgit Geoerger, Ira J. Dunkel, Michael Roughton, Jeea Choi, Lisa Osterloh, Mark Russo, Darren Hargrave
Publikováno v:
Blood Advances.
Langerhans cell histiocytosis (LCH) is a rare, heterogenous, neoplastic disorder primarily affecting children. BRAF mutations have been reported in >50% of patients with LCH. The selective BRAF inhibitor, dabrafenib, in combination with the MEK1/2 in
Autor:
Eric, Bouffet, Birgit, Geoerger, Christopher, Moertel, James A, Whitlock, Isabelle, Aerts, Darren, Hargrave, Lisa, Osterloh, Eugene, Tan, Jeea, Choi, Mark, Russo, Elizabeth, Fox
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
This is a four-part, phase I/II study (ClinicalTrials.gov identifier: NCT02124772) in patients age18 years with relapsed/refractory malignancies: trametinib monotherapy dose finding (part A) and disease-specific expansion (part B), and dabrafenib + t
Autor:
Carlos Perez-Cervantes, Jeffery S. Tessem, Sunyoung Shin, Jason Spaeth, Mary E. Rabaglia, Jeea Choi, Linsin A Smith, Christina Kendziorski, Roland Stein, Alan D. Attie, Shane P Simonett, Kathryn L. Schueler, Mark P. Keller, Jacob A. Herring, Sunduz Keles, Donnie S. Stapleton, Ivan P. Moskowitz, Matthew N. Bernstein, Rhonda Bacher, Chenyang Dong, Daniel R Turkewitz
Publikováno v:
J Clin Invest
The transcription factor NFATC2 induces β cell proliferation in mouse and human islets. However, the genomic targets that mediate these effects have not been identified. We expressed active forms of Nfatc2 and Nfatc1 in human islets. By integrating
Autor:
Michael Roughton, Birgit Geoerger, Jeea Choi, James A. Whitlock, Darren Hargrave, Mark W. Russo, Lisa Osterloh
Publikováno v:
Blood. 138:3618-3618
Introduction: Langerhans cell histiocytosis (LCH) is a rare proliferative disorder associated with varied clinical presentations. Patients (pts) with advanced disease have frequent recurrences despite standard chemotherapy and a significant proportio
Autor:
Chu, Li-Fang, Leng, Ning, Zhang, Jue, Zhonggang Hou, Mamott, Daniel, Vereide, David, Jeea Choi, Kendziorski, Christina, Stewart, Ron, Thomson, James
Experimental outline and qualities of scRNA-seq on human ES-derived progenitors. Figure S2. PCA and heterogeneity analysis of human ES-derived progenitors. Figure S3. Characterizations of the impacts of hypoxia on DE differentiation. Figure S4. Quali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e4a400a2b010a50c68dd24151273f5f
Autor:
Uwe Platzbecker, Maria Socorro O Portella, Honar Cherif, Moshe Mittelman, Michael Dickinson, Jeea Choi, Amit Verma, Pierre Fenaux, Pedro Marques Ramos, Paul Burgess
Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-bli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d66c2374746833a088bdccaf3c0bf7b
https://europepmc.org/articles/PMC6337824/
https://europepmc.org/articles/PMC6337824/
Autor:
Lindsay Kilburn, Kenneth J. Cohen, Eduard Gasal, Darren Hargrave, Isabelle Aerts, Elizabeth Fox, Birgit Geoerger, Karen Wright, James A. Whitlock, Eric Bouffet, Jeea Choi, Mark W. Russo, Cynthia Wetmore, Santhosh A. Upadhyaya, Christopher L. Moertel
Publikováno v:
Neuro-Oncology
BACKGROUND Children with BRAF V600-mutant LGG have suboptimal response to standard chemotherapy. Previously, D (BRAF V600 inhibitor) monotherapy has demonstrated clinical benefit in this population. We report interim analysis results of pediatric pat